AbbVie (TSX:ABBV) Payments of Debt: C$-12,451 Mil (TTM As of Mar. 2026)


TSX:ABBV AbbVie Inc TSX:ABBV
81 GF Score
Price C$35.51
GF Value C$29.99
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Payments of Debt?

AbbVie TSX:ABBV -3.79% 81 Payments of Debt is C$-12,451 Mil as of Mar. 2026. GuruFocus rates TSX:ABBV with a GF Score™ of 81/100 and a GF Value™ of C$29.99 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Payments of Debt for the three months ended in Mar. 2026 was C$-3,429 Mil.

AbbVie's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was C$-12,451 Mil.

AbbVie Payments of Debt Related Terms

AbbVie Payments of Debt Historical Data

* Premium members only.

The historical data trend for AbbVie's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Payments of Debt Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12,049.92 -19,607.23 -5,566.30 -20,830.54 -13,236.30

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,344.13 -5,130.97 -2,788.93 -1,102.22 -3,428.63
TSX:ABBV
81GF Score
AbbVie Inc TSX:ABBV
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-12,451 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of C$-12,451 Mil mean?
AbbVie (TSX:ABBV) has a Payments of Debt of C$-12,451 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AbbVie and its competitors.
Is AbbVie's Payments of Debt too high?
AbbVie's current Payments of Debt is C$-12,451 Mil. Overall, AbbVie has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Payments of Debt compare to MRK and JNJ?
AbbVie's Payments of Debt of C$-12,451 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AbbVie and its competitors. AbbVie's current Payments of Debt is C$-12,451 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (TSX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is C$29.99, compared to a current price of C$35.51 — trading 18.4% above its estimated fair value. The current Payments of Debt is C$-12,451 Mil. AbbVie's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For AbbVie (TSX:ABBV), the current Payments of Debt is C$-12,451 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (TSX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of C$35.51 is trading 18.4% above its estimated GF Value™ of C$29.99. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for TSX:ABBV:

  • Payments of Debt: C$-12,451 Mil
  • GF Value™: C$29.99 vs. price of C$35.51 (18.4% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
81GF Score

Get the complete analysis for TSX:ABBV

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$35.51
Price
C$29.99
GF Value